and tested to be of the same purity and potency as the original. In these recommendations, we refer only to TNFi biosimilars. Examples include infliximab-dyyb, etanercept-szzs, and adalimumab-atto. TNFi Infliximab, etanercept, adalimumab, certolizumab, golimumab, and their biosimilars. TNFi monoclonal antibodies Infliximab, adalimumab, certolizumab, golimumab. Biologics TNFi, abatacept, rituximab, sarilumab, tocilizumab, ustekinumab, secukinumab, ixekizumab.** High-quality evidence Studies that